Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Atrial Fibrillation Recurrence Post-Cardioversion
NCT04155879Unknown
- Sponsor
- Hillel Yaffe Medical Center
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of colchicine in Atrial fibrillation (AFib), sponsored by Hillel Yaffe Medical Center. Primary endpoint: Recurrence of atrial fibrillation at 12 months. Status: unknown.
02
Drugs
colchicine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04155879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155879.